Special Notice: New AD Treatment Lecanemab

Alzheimer’s Disease Treatment Special Notice

On September 27, 2022, the overall results of the large global phase 3 trial of lecanemab were released. This trial was carried out at multiple sites throughout the Unites States and globally, in patients with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s disease). This drug is delivered intravenously and removes Alzheimer’s plaques from the brain. The results of this landmark study are significant: it is the first drug proven to slow the course of Alzheimer’s disease. This drug, lecanemab, is now under consideration by the US Food and Drug Administration for approval but is not yet approved or available commercially at this time.